Articles tagged with Brain Cancer
Scientists at University College London have developed a novel cancer therapy using magnetic seeds guided by an MRI scanner to heat and destroy tumours. The therapy, called MINIMA, has the potential to precisely treat hard-to-reach cancers with minimal side effects.
A study led by RCSI researchers found that almost half of tumours with metastatic breast cancer in the brain have changes in DNA repair pathways, making them vulnerable to PARP inhibitor drugs. This discovery opens up potential novel treatment strategies for patients with limited targeted therapy options.
Researchers discovered that cyclotides from violets increase the power of TMZ in killing glioblastoma cancer cells by up to eight-fold. This breakthrough could lead to better treatment options for patients with this fatal form of brain cancer.
Researchers have developed a novel combination of two drugs delivered in nanoparticles that extend the survival of mice with medulloblastoma. The treatment targets the mTOR pathway and reduces off-target toxicity, making it a potential less toxic alternative to current treatments.
A new study by WVU researcher William Walker found that the blood-brain barrier is dynamic and more receptive to chemotherapy at night. This could lead to better treatment outcomes for patients with brain metastasis.
A UC researcher is leading three projects to study the genetic workings of deadly pediatric brain tumors, including DIPG. The goal is to understand how genes regulate blood vessels and develop more effective treatments. Researchers are also exploring a new drug that targets a specific genetic mutation.
Researchers found that glioma cells with mutated ATRX have reduced Chk1 activity, leading to dysregulated cell cycle and heightened sensitivity to ATM inhibitors. The study suggests that combining radiation therapy with these inhibitors may improve treatment outcomes for patients with this gene mutation.
Researchers found that zika virus injections destroyed brain tumors in mice and reduced tumor size in cerebral organoids, with immune cells alerting the system to its existence. This approach opens up prospects for virotherapy treatment of central nervous system tumors.
Researchers at Massachusetts General Hospital found that inhibiting the OR5B21 gene significantly decreased breast cancer metastasis to the brain, bones and lung. This discovery may lead to new therapeutic targets to prevent or delay breast cancer's spread.
A targeted cancer drug combination has shown clinically meaningful activity in patients with highly malignant brain tumors carrying the rare BRAF v600E mutation, including glioblastomas. The study yielded an encouraging response rate of 33% overall and 69% in low-grade gliomas.
Researchers at Children's National Hospital have successfully developed a personalized T cell immunotherapy that targets and kills unique proteins in individual tumor cells. This approach, combining genetic sequencing and protein identification, offers a promising treatment option for children with hard-to-treat brain tumors.
Researchers identified 166 prognostic biomarkers from long non-coding RNAs, with one biomarker, HOXA10-AS, showing high effectiveness in categorizing gliomas as low- or high-risk. The study provides potential therapeutic targets and insights into cancer biology.
A study found that patients from ethnic minority groups had lower mortality rates compared to white British people. Patients from Indian, Pakistani, and other ethnic backgrounds were 16-30% less likely to die within one year of diagnosis.
Researchers at UBC and BC Cancer developed a new test to distinguish between high-risk medulloblastoma cases requiring radiation therapy and lower-risk cases. This test has the potential to improve diagnosis and future treatment of childhood brain tumours worldwide, reducing unnecessary side effects and increasing cure rates.
Researchers at Massachusetts General Hospital have found that immune checkpoint inhibitors can generate promising results in patients with leptomeningeal carcinomatosis (LMD), a rare complication of cancer. The treatment showed increased activity in cancer-killing immune cells and expression of particular genes within cells.
Pediatric oncologist Adam Green and his team have discovered genetic mutations that may predict the development of these secondary tumors, allowing for early detection and alternative treatments. They are also exploring FDA-approved chemotherapy drugs as potential treatments.
Researchers analyzed data from over 3,200 brain metastatic tumors and discovered that different types of cancer tend to spread to specific parts of the brain. The study's findings may help predict where a particular cancer will metastasize and inform treatment strategies.
A chemical engineer is developing a novel biomaterial that can mimic the response of pediatric brain cancers to different approaches, allowing for customized treatment plans. The material will be designed to simulate the growth environment of cancer cells inside a tumor and can be used with patient-derived cells.
A modified ketogenic diet was found to be safe and feasible for people with brain tumors called astrocytomas. The diet led to changes in metabolism in the body and brain, including decreased hemoglobin A1c levels, increased lean body mass, and alterations in brain metabolites.
A study coordinated by the University of Trento identified the cell of origin of medulloblastoma, a common and aggressive childhood brain cancer. The researchers used organoids, three-dimensional models of tumor tissue, to understand the genetic mechanisms responsible for this type of brain cancer.
Researchers found a highly effective treatment for high-risk neuroblastoma and other forms of aggressive childhood cancer. The combination of CBL0137 and panobinostat resulted in remarkable growth suppression and an immune response that targeted cancer cells.
Australian researchers have discovered a new therapeutic approach for treating Diffuse Intrinsic Pontine Glioma (DIPG), a currently incurable brain cancer in children. Using the anti-cancer compound CBL0137, which targets the key genetic driver of DIPG, has shown promising results in both laboratory tests and animal models.
A large-scale study found that people living in areas with high background radiation had a 2.5-year longer life expectancy and lower rates of certain cancers, including lung, pancreatic, colon, and rectal cancer. The researchers suggest re-evaluating the linear no-threshold paradigm for low-dose radiation.
A novel combination treatment approach has shown encouraging results in mice with tumors similar to human astrocytomas. The treatment, which blocks D-2-HG production and inhibits an immune checkpoint protein, led to tumor regression in 60% of treated animals, improving survival rates.
A new study suggests a link between Toxoplasma gondii infection and the risk of glioma, a type of brain cancer, in adults. Researchers found that people with glioma were more likely to have antibodies to T.gondii than those without the disease.
A new study will investigate the safety of proton therapy for children with brain cancer compared to conventional x-ray radiation. The researchers aim to assess the risk of developmental disorders in children as a result of using proton beams to treat paediatric brain tumours.
A new study suggests that controlling two proteins, ANP32E and H2AZ, could prevent cancer by regulating cell division and tumor growth. With high levels of H2AZ found in breast and brain cancers, targeting these proteins may make cancer cells more sensitive to anti-cancer drugs or immune-system attack.
Scientists identify how single gene loss fuels deadly childhood brain cancer by studying human stem cells and neural development. The study reveals that the loss of SMARCB1 leads to resistance to final cell differentiation and defect in maintaining normal cell health.
Researchers have discovered genes that facilitate the penetration of cancer cells into the brain, a process that complicates cancer treatment. The study highlights potential targets for therapy, including enzymes and microRNAs involved in disrupting blood-brain barrier integrity.
A highly sensitive blood test can accurately diagnose and classify different types of brain tumours without the need for tissue samples. This breakthrough has the potential to transform patient care by providing more accurate diagnosis, less invasive methods and better treatment planning.
A study found increased cancer risks in two regions of Switzerland, particularly brain tumors, due to localized factors. The research suggests a need for intensified search for environmental risk factors and separate consideration of different brain tumor subgroups.
A new study has identified a potent Nrf2 inhibitor, triptolide, as a promising therapeutic approach for IDH1-mutated glioma. The research reveals that disrupting the glutathione synthesis pathway establishes synergistic lethality with a neomorphic IDH1 mutation.
Researchers found that osimertinib, commonly used to treat non-small cell lung cancer, showed benefits for patients with metastatic brain cancers, with 64% experiencing a measurable response and 90% disease control in the central nervous system.
A study published in Neuro-Oncology Advances suggests that chemotherapy can be effective against diffuse intrinsic pontine glioma (DIPG), a devastating childhood brain cancer. Researchers found that the medicine reaches DIPG tissue in good quantities, offering new hope for treatment.
A study confirms racial disparities in treatment outcomes for pediatric brain cancer patients, with Black and Hispanic patients facing poorer prognoses after diagnosis and treatment, regardless of stage at diagnosis.
A new study led by TGen suggests that tumor microenvironment plays a vastly under-studied role in cancer development and growth. By analyzing genetic sequencing, single-cell analysis, and high-resolution medical imaging, researchers can provide timely information on how to best attack each patient's cancer.
The University of Trento led a research study to create in vitro tumor models using organoids, which can show signs of disease and provide a model of tumors affecting young patients. The study confirmed the key role of two proteins and investigated therapeutic options, making it possible to advance brain cancer research.
Scientists are exploring genetic changes that make brain tumors resistant to BRAF inhibitors, a common treatment for certain types of brain cancer. The study aims to identify new potential targets for combination therapy to keep cancers from developing resistance.
Researchers found that surgically removing the entire tumor can boost median survival length from eight months to 16 months or more. The study analyzed data from 103 patients and suggests surgery may be a viable treatment option for brainstem high-grade gliomas, which are rare and deadly brain cancers.
A new study from Massachusetts General Hospital suggests that glowing particles in the blood of patients with brain cancer may be used to diagnose and monitor the disease. The discovery uses a substance called 5-aminolevulinic acid, which makes tumor cells fluorescent, allowing for non-invasive blood tests.
A study published in Acta Neuropathologica has identified an epigenetic lesion called NSUN5 that can predict good clinical course in 15% of patients with gliomas, a type of brain cancer. The researchers found that this alteration allows the tumor to grow slowly and enables patients to survive longer.
Researchers have discovered a new type of drug that targets the genetic weakness in 'diffuse intrinsic pontine glioma', a devastating childhood brain cancer. The treatment also shows promise for patients with stone man syndrome, a rare genetic disease where muscles and ligaments turn to bone. Clinical trials are expected to begin in 2021.
Research analyzed rates of brain metastases in elderly patients with breast cancer, lung cancer, and melanoma. The study found that these cancers carry a significant risk of developing brain metastases later in life, with varying rates among primary cancer types.
Researchers have developed new Cryo-Chip substrates that improve contrast and specimen retention in cryo-electron microscopy (cryo-EM) imaging. These advancements enable faster data acquisition, leading to more efficient analysis of macromolecules in various biological systems.
Researchers found that estrogen affects astrocytes, which produce growth factors promoting brain metastasis. Anti-estrogen therapy may prevent brain metastasis in women with triple-negative breast cancer.
Researchers used a compound to highlight fast-growing cancer cells, allowing surgeons to distinguish between high-grade and low-grade glioma cells. This technique improves the accuracy of diagnosing high-grade glioma during surgery, potentially increasing patient survival.
Research by Norwegian University of Science and Technology found that individuals with larger brains are more likely to develop brain tumors. The study, which analyzed data from over 1,000 participants, revealed a statistically significant association between brain size and increased cancer risk.
Researchers have identified NOTCH 1 as a key player in the metastasis of medulloblastoma, a type of pediatric brain cancer. The study also suggests that targeting this protein could lead to a more effective treatment option with fewer side effects.
Researchers at Henry Ford Health will explore genetic makeup of gliomas to identify new therapies, building on previous discoveries about DNA methylation and molecular signatures.
Researchers found that a typical mutation in cancer cells blocks the body's immune response, even with immunotherapy. The tumor releases an oncometabolite that impairs T cell function, leading to re-programmed immune cells.
A recent in-vivo study published in Nature Communications found that the nucleus accumbens, a part of the brain with weak connections, plays an unexpectedly influential role in enhancing the memory network. This research has implications for understanding diseases like Alzheimer's and brain cancer affecting cognitive functions.
The Pew scholars in the biomedical sciences will receive four-year grants to advance their explorations of biological mechanisms underpinning human health and disease. The research aims to solve biomedical puzzles including cancer, infectious diseases, and psychiatric disorders.
Researchers developed an algorithm to predict treatment effectiveness in individual patients using a molecular communication pathway. The study found that repurposing ruxolitinib, a drug approved for malignant blood disorders, can overcome resistance to measles virotherapy by increasing its effectiveness by a factor of 1,000.
Researchers propose novel molecular therapy to treat deadly pediatric brain cancer, effective in preclinical tests and humanized mouse models. The compound triggers DNA damage in cancer cells, disrupting telomere function and killing brain cancer stem cells.
A study found that targeted cancer drugs can cause cognitive and behavioral deficits in young mice, but these effects can be reversed with environmental stimulation and physical exercise. Researchers suggest that pediatric brain cancer patients may experience similar side effects, highlighting the need for remediation efforts.
Researchers have discovered how CAR-T cell therapy kills cancer cells, revealing a key mechanism that can inform the design of safer and more efficient treatments. The study could pave the way for the adaptation of CAR-T therapy to treat solid cancers, including notoriously hard-to-treat brain tumors.
Researchers have found that PD-1 inhibitors can be effective in treating supratentorial pediatric ependymoma, a type of brain cancer with poor prognosis. The study identified RELA-fusion as a genetic cause and showed that these tumors express high levels of PD-L1, which can be targeted by PD-1 inhibitors.
Researchers have discovered that three distinct varieties of the protein AKT play different roles in brain health, with AKT2 targeting brain cancer and AKT1 promoting memory formation. The study's findings hold promise for developing targeted therapies for conditions like Alzheimer's disease and schizophrenia.
A team of scientists has identified molecular super enhancers that regulate tumor development in ependymoma, a common type of brain cancer in children. By targeting these enhancers, researchers have shown promise in slowing down or stopping the growth of ependymoma cells.
Researchers have developed a novel laboratory model that replicates key hallmarks of pediatric high-grade glioma, a devastating illness and leading cause of death in children. Mutations in histone 3.3 are believed to play a pivotal role in its development, with the new model supporting the concept that cancer starts in utero.